Company: PRME
Filing Date: 2025-07-14
Form Type: DEF 14A
Source: 0001193125-25-158716
Chunk: 0

Company: Prime Medicine, Inc.
Filing Date: 2025-07-14
Form: DEF 14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

| Filed by the Registrant |     | ☒ |     | Filed by a Party other than the Registrant |     | ☐ |

Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☒ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| ☐ | Soliciting Material under §240.14a-12 |

PRIME MEDICINE, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table below in exhibit required by Item 25(b) Exchange Act Rules 14a-6(i)(14) and 0-11. |

PRIME MEDICINE, INC. 60 First Street Cambridge, MA 02141 NOTICE OF 2025 SPECIAL MEETING OF STOCKHOLDERS To Be Held On August 1, 2025 Notice is hereby given that a special meeting of stockholders (the “Special Meeting”) of Prime Medicine, Inc., a Delaware corporation (the “Company”), will be held on August 1, 2025, at 1:00 p.m., Eastern Time, in a virtual meeting format, which will be conducted via live webcast. You may attend the Special Meeting online, vote your shares electronically and submit questions by visiting www.virtualshareholdermeeting.com/PRME2025SM. The Special Meeting will be held for the following purposes:

| 1. | To approve the repricing of certain outstanding stock options that have been granted under the                                                                                                                                     
 Company’s 2019 Stock Option and Grant Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the “2019 Plan”) and/or the 2022 Stock Option and Incentive Plan (as may be amended, 
 restated or otherwise modified from time to time in accordance with its terms,